Sarcopenia
Welcome,         Profile    Billing    Logout  
 46 Companies   12 Products   12 Products   17 Mechanisms of Action   756 Trials   22406 News 


«12...236237238239240241242243244245246...401402»
  • ||||||||||  Preclinical, Journal:  Moderators of skeletal muscle maintenance are compromised in sarcopenic obese mice. (Pubmed Central) -  Nov 12, 2021   
    Myotubes pretreated with plasma from aged NC fed mice had 14% smaller myotube diameter than their aged HFD counterparts. Aged obese mice had greater impairments to mediators of muscle maintenance as evident by reductions in muscle mass, CSA, along with alterations in cell cycle regulation and inflammatory and insulin signaling.
  • ||||||||||  Biomarker, Journal:  Prediction of sarcopenia using a battery of circulating biomarkers. (Pubmed Central) -  Nov 12, 2021   
    A significantly higher incidence of clinical sarcopenia was found in high-risk group. Taken together, the battery of biomarkers can be an effective tool in the early diagnosis and assessment of sarcopenia.
  • ||||||||||  Victoza (liraglutide) / Novo Nordisk
    Clinical, Journal:  Approach to Obesity in the Older Population. (Pubmed Central) -  Nov 12, 2021   
    The use of weight loss medications, particularly glucagon-like peptide-1 analogs (liraglutide as the first example), provides an additional treatment tier...Risk-benefit issues should be considered with extreme care and disclosed to candidates. The selection process requires good presurgical functional status, individualized consideration of the sequels of obesity, and reliance on centers that are highly experienced in the surgical procedure as well as short-term and long-term subsequent comprehensive care and support.
  • ||||||||||  Trial completion:  The BRAINFOOD Trial to Prevent Recurrent Hepatic Encephalopathy. (clinicaltrials.gov) -  Nov 11, 2021   
    P=N/A,  N=12, Completed, 
    Both sarcopenia and sarcopenic obesity are associated with an increased long-term risk of impaired cognitive function in older adults. Active, not recruiting --> Completed
  • ||||||||||  Clinical, Journal:  Radiological parameter associated with the survival of old patients with hip fracture. (Pubmed Central) -  Nov 11, 2021   
    We did not find a significant difference between the intertrochanteric and femoral neck fracture groups with regard to CCR, CTI and Dorr type. However, the rate of femoral calcification in both the fracture and unaffected sides was significantly higher in the intertrochanteric group.
  • ||||||||||  Journal:  Sarcopenic obesity is the real problem in COVID-19 ! (Pubmed Central) -  Nov 11, 2021   
    Our study demonstrated that walking > 45 min daily (Calories = METs (walking: 3.0) × duration of time (h) × weight (60 kg) × 1.05) can reduce paraspinal muscle loss, which may in turn decrease the risk of falls, low-back pain, and sarcopenia. No abstract available
  • ||||||||||  Biomarker, New trial:  Nutritional Biomarkers of Sarcopenia (clinicaltrials.gov) -  Nov 10, 2021   
    P=N/A,  N=35, Not yet recruiting, 
  • ||||||||||  Review, Journal:  Sarcopenia Assessment Techniques. (Pubmed Central) -  Nov 10, 2021   
    Muscle mass indicators (SMA and SMIs) and muscle quality indicators (SMD, IMAT, and IMAT/SMA) measured by chest CT images are valuable for diagnosing sarcopenia and myosteatosis, respectively. Content available: Author Audio Recording.
  • ||||||||||  Journal:  BandPass: A Bluetooth-Enabled Remote Monitoring Device for Sarcopenia. (Pubmed Central) -  Nov 10, 2021   
    BandPass was successfully able to measure force continuously over time during exercises, measure longitudinal compliance with exercises, and quantify force continuously over time. A mobile health (mHealth) force-sensing system allows for the remote monitoring of prescribed in-home resistance exercise band programs for at-risk older adults, bridging the gap between clinicians and patients.
  • ||||||||||  Observational data, Journal:  Relationship Between Low Skeletal Muscle Mass and Arteriosclerosis in Western China: A Cross-Sectional Study. (Pubmed Central) -  Nov 10, 2021   
    Low skeletal muscle mass was significantly associated with arteriosclerosis (OR: 1.435, 95% CI: 1.343-1.533, P < 0.001) in all subjects, and the association remained significant in young age (OR: 1.506, 95% CI: 1.353-1.678, P < 0.001), middle-age (OR: 1.329, 95% CI: 1.195-1.479, P < 0.001), and old age (OR: 1.676, 95% CI: 1.191-2.358, P = 0.003), and also significant in men (OR: 1.559, 95% CI: 1.396-1.740, P < 0.001) and women (OR: 1.266, 95% CI: 1.143-1.401, P < 0.001). Conclusions and Implications: Our results show that the prevalence of low muscle mass and arteriosclerosis is high in the general population, even among middle-aged people and young people, and confirmed that there is a significant independent association between low skeletal muscle mass and arteriosclerosis in all subjects and in different age and gender subgroups.
  • ||||||||||  Trial completion date, Trial primary completion date:  Microbiome and Sarcopenia in Patients With Liver Cirrhosis (clinicaltrials.gov) -  Nov 9, 2021   
    P=N/A,  N=120, Recruiting, 
    Myostatin in combination with CPK or albumin are good surrogate markers in excluding sarcopenia. Trial completion date: Dec 2021 --> Dec 2024 | Trial primary completion date: Jul 2021 --> Jul 2023
  • ||||||||||  Clinical, Journal:  Malnourished cirrhotic patient: what should we do? (Pubmed Central) -  Nov 6, 2021   
    Novel strategies to reverse sarcopenia such as hormone supplementation, long-term ammonia-lowering agents and myostatin antagonists, are currently under investigation. Malnutrition, sarcopenia and frailty are unique, inter-related and multidimensional problems in cirrhosis which require special attention, prompt assessment and appropriate management as they significantly impact morbidity and mortality.